Sign in
Taking people in United StatesPhase 2

Lowering dexamethasone doses after brain tumor surgery to see effects on steroid side effects

Tests gradually lowered dexamethasone doses in adults after surgery for a brain tumor.

Key facts

Who runs it
Emory University
Where
Atlanta, United StatesSee the site
Trial code
Registry title
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
Status
Recruiting
Phase
Phase 2
People taking part
200 people, planned
Started
9 Jan 2025
Expected to end
30 Jul 2028
Type of study
Interventional, 2 groups
Treatments tested
  • Biospecimen Collection
  • Computed Tomography
  • Dexamethasone
  • Magnetic Resonance Imaging
  • Questionnaire Administration
Record updated
10 February 2026

Who can take part

The trial is looking for adults having surgery to remove a brain tumor (craniotomy). It compares two ways of lowering dexamethasone doses after surgery.

Age
18 years and older
Sex
All sexes
Disease stage
Scans showing a high-grade glioma (HGG), low-grade glioma (LGG), meningioma, or brain metastasis (cancer spread to the brain).
Earlier treatment
People who took daily corticosteroids for more than two weeks recently, or more than the equivalent of 85 mg of dexamethasone in the last month, cannot join. People taking drugs that weaken the immune system cannot join.
Main reasons for not taking part
  • Known problems with the hypothalamic-pituitary-adrenal (HPA) hormone system, or a tumor pressing on the sella or affecting the pituitary gland
  • Known immune deficiency, or current lymphoma or leukemia
  • Past solid organ transplant
  • Pregnant women
  • Past stroke that left a nerve or brain deficit
Show the full registry criteria (11)Hide the full registry criteria

Who can take part

  • Patients with radiographic findings consistent with either HGG, LGG, Meningioma, or brain metastasis
  • Age equal to or above 18

Who cannot take part

  • Taking immunosuppressive drugs - including but not limited to methotrexate, mycophenolate, rapamycin, tacrolimus, adalimumab, infliximab. Greater than two weeks of recent daily corticosteroid use or the use of corticosteroids equivalent to > 85 mg of dexamethasone in the last month
  • History of solid organ transplant
  • History of cerebrovascular accident leading to neurologic deficit
  • Known hypothalamic-pituitary-adrenal (HPA) axis dysfunction
  • Tumor causing compression of the sella or pituitary dysfunction
  • Known immunodeficiency - including but not limited to severe combined immunodeficiency (SCID), common variable immunodeficiency (CVID), lymphocytopenia
  • Current lymphoma or leukemia
  • Minors < 18
  • Pregnant women

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age

This trial is currently available in United States.

  • Emory University Hospital/Winship Cancer InstituteAtlanta, United StatesContact: Agnes HarutyunyanTaking people

About the trial

What the trial wants to find out

This phase II trial tests the effect of decreasing (tapering) doses of dexamethasone on steroid side effects in patients after surgery to remove (craniotomy) a brain tumor. Steroids are the gold standard post-surgery treatment to reduce swelling (edema) at the surgical site to reduce neurological symptoms. Although, corticosteroids reduce edema, they have side effects including high blood sugar, high blood pressure, and can impair wound healing. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response. It also works to treat other conditions by reducing swelling and redness. Tapering doses dexamethasone may decrease steroid side effects without increasing the risk of edema in patients with brain tumors after a craniotomy.

The 2 groups in the trial

  • Arm I (NDS)Treatment being tested

    Patients receive tapering doses of dexamethasone on days 1-15. Patients also undergo blood sample collection at time of surgery, at follow up visits and optionally at wound check visit 10-14 days post operative at investigator availability. Patients additionally undergo MRI and CT scan during inpatient stay as part of standard of care.

    Treatment: Biospecimen Collection, Computed Tomography, Dexamethasone, Magnetic Resonance Imaging, and Questionnaire Administration

  • Arm II (RDS)Treatment being tested

    Patients receive tapering doses of dexamethasone on days 1-4. Patients may receive dexamethasone IV and restart the taper if clinically indicated. Patients also undergo blood sample collection at time of surgery, follow up visits and optionally at wound check visit 10-14 days post operative at investigator availability. Patients additionally undergo MRI and CT scan during inpatient stay as part of standard of care.

    Treatment: Biospecimen Collection, Computed Tomography, Dexamethasone, Magnetic Resonance Imaging, and Questionnaire Administration

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Post-Operative Dosing of Steroids Post Craniotomy for Brain Tumor (PODS)
Plain-language title
Lowering dexamethasone doses after brain tumor surgery to see effects on steroid side effectsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT06132685, who can take part
Record updated
10 February 2026